Regulations.gov document
Response Letter from FDA CDER to Keryx Biopharmaceuticals, Inc.
Other · FDA-2018-P-3284 · posted Jan 31, 2019
Key facts
| Document ID | FDA-2018-P-3284-0022 |
|---|---|
| Title | Response Letter from FDA CDER to Keryx Biopharmaceuticals, Inc. |
| Document type | Other |
| Subtype | Agency Response |
| Agency | FDA |
| Docket | FDA-2018-P-3284 |
| Posted | Jan 31, 2019 |
| Comment period opens | Jan 31, 2019 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: